Among 1083 proposals, Nectin emerged as one of the 42 recipients of EIC funding, highlighting the promise of its groundbreaking cancer immunotherapy pipeline.
Nectin has received an initial grant of €2.5M and stands to potentially secure up to €15M in equity, from the European Innovation Council and SMEs Executive Agency (EISMEA).
With this grant, Nectin will continue developing its innovative immunotherapy drug candidate, paving the way for significant advancements in cancer care and potentially offering new hope for patients.
This marks Peregrine’s second company to receive this accolade, a rare achievement both in Europe and, particularly, in Israel. Restore Medical was the initial recipient.
